Ron C. Hoogeveen, Ph.D.
- Assistant Professor of Medicine
- Co-Director, The Maria and Alando J. Ballantyne, M.D., Atherosclerosis Clinical Research Laboratory
Basic and Clinical Research Interests:
Dr. Hoogeveen's basic research interests focus on the molecular biology and biochemistry of sterol and lipid metabolism. Of particular research interest is the role of oxidative stress and dyslipidemia in the etiology of cardiovascular disease and diabetes. Current studies examine the role of oxidatively modified sterols and lipids in the development of cardiovascular disease, diabetes, and the metabolic syndrome. As the Co-Director of The Maria and Alando J. Ballantyne, M.D., Atherosclerosis Clinical Research Laboratory, which serves as the core laboratory for the Atherosclerosis Risk in Communities (ARIC) study, Dr. Hoogeveen is directly involved in assay development. Recent validation studies of a novel assay for lipoprotein-associated phospholipase A2 (Lp-PLA2) in the ARIC study cohort have led to FDA approval for the PLAC-test as a biomarker for cardiovascular risk. The discovery of novel biomarkers might be useful in identifying individuals at high risk for cardiovascular disease, the metabolic syndrome and diabetes.
- Hoogeveen RC, Ballantyne CM, Bang H, Heiss G, Duncan BB, Folsom AR, Pankow JS. Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Diabetologia 2007;50:36-42.
- Gaubatz JW, Gillard BK, Massey JB, Hoogeveen RC, Huang M, Lloyd EE, Raya JL, Yang CY, Pownall HJ. Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). J Lipid Res 2007;48:348-357.
- Schmidt MI, Duncan BB, Vigo A, Pankow JS, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G; the ARIC Investigators. Leptin and incident type 2 diabetes: risk or protection? Diabetologia 2006;49:2086-2096.
- Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharrett AR, Boerwinkle E. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005;165:2479-2484.
- Hoogeveen RC, Morrison A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR, Ballantyne CM. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 2005;183:301-307.
- Liu MY, Xydakis AM, Hoogeveen RC, Jones PH, Smith EO, Nelson KW, Ballantyne CM. Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma,uusing the Luminex-100 system. Clin Chem 2005;51:1102-1109.
- Hoogeveen RC, Ballantyne CM. PLAC test for identification of individuals at increased risk for coronary heart disease. Expert Rev Mol Diagn 2005;5:9-14.
- Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2004;53:2473-2478.
- Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109:837-842.
- Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey DL, Jaffe JS, Oppermann S, Kahan BD, Morrisett JD. Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation 2001;72:1244-1250.